ALIVUSAlivus Life Sciences Ltd.

    Alivus Life Sciences Ltd: results and news

    Every Alivus Life Sciences Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings, mergers & acquisitions.

    2 articles · pharmaceuticals · Latest 11 Nov 2026

    ALIVUSAlivus Life Sciences Ltd.

    Alivus Life Sciences Q2 FY27 Results: Standalone Net Profit ₹197 Crore on Total Income of ₹702 Crore

    Alivus Life Sciences (NSE: ALIVUS) reported standalone total income of ₹701.90 crore and net profit of ₹196.75 crore for the quarter ended 30 Sep 2026, it said in a filing on 29 Oct 2026. The results are presented on a standalone basis because the company's newly incorporated Brazilian subsidiary had no transactions requiring consolidation.

    • Earnings
    • Active Pharmaceutical Ingredients

    Blacklitt Research2 min read